More Healthcare Coverage

Expert Analysis

• Next Steps For Ill. Tort Defendants After Cotton V. Coccaro

  

  While an Illinois appeals court's ruling in Cotton v. Coccaro recently upheld the constitutionality of the state's law imposing prejudgment interest in personal injury and wrongful death actions, defendants can still raise constitutional challenges to the law pending Illinois Supreme Court review, says Melissa Murphy-Petros at Wilson Elser.

• NBA Players Must Avoid Legal Fouls In CBD Deals

  

  The NBA’s recently ratified collective bargaining agreement allows athletes to promote CBD brands and products, but athletes and the companies they promote must be cautious of a complex patchwork of applicable state laws and federal regulators’ approach to advertising claims, says Airina Rodrigues at Brownstein Hyatt.

• What Purdue Ch. 11 Means For Future Of Third-Party Releases

  

  The Second Circuit’s highly anticipated ruling approving Purdue Pharma’s bankruptcy plan establishes stringent factors that lower courts must consider before approving nonconsensual third-party releases, but the circuit split on the matter means the issue is far from resolved, say Gregory Hesse and Kollin Bender at Hunton.

• Preparing For Md. Adult-Use Cannabis: Operations And More

  

  As a new regulatory body takes the reins before Maryland’s adult-use cannabis market launches on July 1, industry stakeholders should understand key provisions related to management agreements, secured creditors and receiverships, dispensary operations, and hemp, say Seth Gitner and Jonathan Havens at Saul Ewing.

• Takeaways From Tribes' High Court Adoption Case Victory

  

  The U.S. Supreme Court's decision in Haaland v. Brackeen, upholding the Indian Child Welfare Act, leaves the door open for individuals to bring equal protection claims, but generally bodes well for future tribal issues that reach the court, says Sarah Murray at Brownstein Hyatt.

• High Court Underscores DOJ's Role In Policing FCA Litigation

  

  The U.S. Supreme Court's decision in Polansky v. Executive Health Resources reaffirms that the government has final say in False Claims Act cases, allowing for meaningful guardrails that deter private litigators from seeking to regulate industries that Congress has delegated to expert administrative agencies, say attorneys at Ropes & Gray.

• What The Data Says About FDA Responses To FOIA Requests

  

  A statistical evaluation of the U.S. Food and Drug Administration's response times to Freedom of Information Act requests in the last decade shows that the FDA handles the majority of requests within a reasonable time frame, but its slowest response times are somewhat concerning, says Bradley Thompson at Epstein Becker.

• Despite Its Plan Objections, UST Also Won In Purdue Ch. 11

  

  The Second Circuit’s recent decision approving Purdue Pharma’s reorganization plan is a win even for the dissenting Office of the U.S. Trustee because the decision sets extremely stringent guidelines for future use of nonconsensual third-party releases, say Edward Neiger and Jennifer Christian at Ask.

• What Courts Say About Workers' Comp And Medical Marijuana

  

  Whether employers and insurance carriers are required or allowed to reimburse employees for out-of-pocket costs for treating work-related injuries with medical marijuana has spawned a debate, and the state courts that have addressed this matter are split on a number of issues, say Alexandra Hassell and Anthony Califano at Seyfarth.

• Health Staffing Shortages May Draw More Antitrust Scrutiny

  

  Though courts have been historically hesitant to police hospital staffing under antitrust laws, recent staffing shortages in the health care industry have created a stronger need to preserve competition in the market and will likely result in crackdown efforts from courts, say Dylan Newton and Michael Horn at Archer & Greiner.

• State Laws Could Complicate Employer Pandemic Protocols

  

  If the recent wave of state bills that would prevent employers from implementing certain safety protocols in a future pandemic is signed into law, companies — especially those that operate across state lines — will be forced to completely rewrite their pandemic playbooks to avoid compliance issues and discrimination claims, says Karla Grossenbacher at Seyfarth Shaw.

• How Telemedicine Providers Can Adapt To Post-COVID Rules

  

  Telemedicine providers should pay close attention to the U.S. Drug Enforcement Administration's temporary rule extending pandemic-era flexibilities for prescribing controlled substances and utilize this brief reprieve to prepare for significant changes in the final permanent rules to come, say Chris Eades and Mayo Alao at Hall Render.

• A Watershed Moment For Microbiome-Based Therapy

  

  While there has been limited microbiome patent enforcement so far, the regulatory approvals of three microbiome-related products and the case of Ferring v. Finch indicate that microbiome patent litigation could take off, and may spur greater investment in this space, say Mark FitzGerald and Alissa Young at Nixon Peabody.